Amedeo Smart

Free Medical Literature Service


 

Amedeo

Multiple Sclerosis

  Free Subscription

09.06.2025

1 Ann Neurol
3 BMC Neurol
1 J Clin Invest
3 J Neurol
1 J Neurol Neurosurg Psychiatry
1 Magn Reson Med
3 Mult Scler
3 Neurology



    Ann Neurol

  1. SABATINO JJ JR, Cree BAC, Hauser SL
    New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond.
    Ann Neurol. 2025 Jun 6. doi: 10.1002/ana.27270.
    >> Share


    BMC Neurol

  2. YALCIN GY, Tulek Z, Kurtuncu M
    Effect of a nurse-led online patient support program on fatigue, sleep and quality of life in patients with multiple sclerosis: a quasi-experimental study.
    BMC Neurol. 2025;25:238.
    >> Share

  3. AZIMIRAD M, Hamtaeigashti S, Raeisi H, Looha MA, et al
    Prevalence of epsilon toxin-producing Clostridium perfringens isolates among patients with multiple sclerosis and neuromyelitis optica spectrum disorder in Iran.
    BMC Neurol. 2025;25:234.
    >> Share

  4. KOUCHAKI E, Bayat S, Asgarian FS
    Sleep disorders in patients with multiple sclerosis.
    BMC Neurol. 2025;25:237.
    >> Share


    J Clin Invest

  5. POLONIO CM, Quintana FJ
    Therapeutic B cell depletion identifies immunoregulatory networks.
    J Clin Invest. 2025;135:e189442.
    >> Share


    J Neurol

  6. CHEN H
    A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS).
    J Neurol. 2025;272:445.
    >> Share

  7. MALUCCHI S, Bava CI, Valentino P, Martire S, et al
    Correction: In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting.
    J Neurol. 2025;272:444.
    >> Share

  8. NEYAL N, Krey KJ, Morrison HA, Nathoo N, et al
    From checkboxes to emojis: a novel approach to patient-reported outcomes in multiple sclerosis.
    J Neurol. 2025;272:434.
    >> Share


    J Neurol Neurosurg Psychiatry

  9. YAMOUT B, Alroughani R, Mohamed SFA, Al-Mahdawi AM, et al
    Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study.
    J Neurol Neurosurg Psychiatry. 2025 Jun 1:jnnp-2024-335704.
    >> Share


    Magn Reson Med

  10. BALAJI S, Wiley N, Dvorak A, Padormo F, et al
    Magnetization transfer imaging using non-balanced SSFP at ultra-low field.
    Magn Reson Med. 2025;94:602-614.
    >> Share


    Mult Scler

  11. MOCCIA M
    Clinical commentary to gender-affirming interventions and prognosis in multiple sclerosis.
    Mult Scler. 2025 Jun 3:13524585251341177. doi: 10.1177/13524585251341177.
    >> Share

  12. NEYAL N, Nathoo N, Cathcart-Rake EJ, Kantarci OH, et al
    Gender-affirming interventions and prognosis in multiple sclerosis.
    Mult Scler. 2025 Jun 3:13524585251341174. doi: 10.1177/13524585251341174.
    >> Share

  13. NOVAKOVA L, Rosenstein I, Axelsson M, Schoonheim MM, et al
    Plateau of practice effects and noise with repeat SDMT testing and in multiple sclerosis.
    Mult Scler. 2025 May 31:13524585251344794. doi: 10.1177/13524585251344794.
    >> Share


    Neurology

  14. JIA A, Price TR, Rosner J, Broderick C, et al
    Journal Club: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e213663.
    >> Share

  15. GOYNE C, Fair AE, Yilmaz D, Race J, et al
    Epigenetic Aging in Pediatric-Onset Multiple Sclerosis.
    Neurology. 2025;104:e213673.
    >> Share

  16. YEH EA
    Accelerated Aging in Children With Multiple Sclerosis: Can We Stop the Clock?
    Neurology. 2025;104:e213840.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016